• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunotherapy in lung cancer: the chemotherapy conundrum.

作者信息

Buddharaju Laxmi Narayana R, Ganti Apar Kishor

机构信息

Division of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.

Division of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA; Division of Oncology-Hematology, Department of Internal Medicine, VA-Nebraska, Western Iowa Health Care System, Omaha, NE, USA.

出版信息

Chin Clin Oncol. 2020 Aug;9(4):59. doi: 10.21037/cco.2020.01.05. Epub 2020 Feb 4.

DOI:10.21037/cco.2020.01.05
PMID:32036674
Abstract
摘要

相似文献

1
Immunotherapy in lung cancer: the chemotherapy conundrum.肺癌中的免疫疗法：化疗难题
Chin Clin Oncol. 2020 Aug;9(4):59. doi: 10.21037/cco.2020.01.05. Epub 2020 Feb 4.
2
Quantifying the benefit of non-small-cell lung cancer immunotherapy.量化非小细胞肺癌免疫疗法的益处。
Lancet. 2019 Nov 23;394(10212):1904. doi: 10.1016/S0140-6736(19)32503-6.
3
Quantifying the benefit of non-small-cell lung cancer immunotherapy - Authors' reply.非小细胞肺癌免疫治疗获益的量化——作者回复
Lancet. 2019 Nov 23;394(10212):1904-1905. doi: 10.1016/S0140-6736(19)32605-4.
4
Immunotherapy: pembrolizumab-is the writing on the wall for cancer?免疫疗法：帕博利珠单抗——癌症的不祥之兆？
Nat Rev Clin Oncol. 2015 Jul;12(7):371. doi: 10.1038/nrclinonc.2015.85. Epub 2015 May 12.
5
Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer.非小细胞肺癌免疫检查点阻断剂长期疗效预测的进展
Immunotherapy. 2019 Aug;11(12):993-1003. doi: 10.2217/imt-2019-0107. Epub 2019 Jul 19.
6
Research round-up: lung cancer.研究综述：肺癌
Nature. 2020 Nov;587(7834):S8-S9. doi: 10.1038/d41586-020-03153-z.
7
Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report.白细胞介素-6作为接受免疫检查点阻断治疗的非小细胞肺癌患者免疫相关不良事件的潜在介质之一：来自一例病例报告的证据
Acta Oncol. 2018 May;57(5):705-708. doi: 10.1080/0284186X.2017.1406668. Epub 2017 Nov 24.
8
Atezolizumab and Its Many Uses.
Oncology (Williston Park). 2019 Aug 23;33(8):683723.
9
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?在联合化疗的情况下，哪种免疫疗法是晚期鳞状非小细胞肺癌的最佳选择：抗 PD-1 还是抗 PD-L1？
J Immunother Cancer. 2018 Dec 3;6(1):135. doi: 10.1186/s40425-018-0427-6.
10
Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?铂类化疗在晚期非小细胞肺癌一线治疗中仍有作用吗？
J Clin Oncol. 2019 Mar 1;37(7):529-536. doi: 10.1200/JCO.18.01534. Epub 2019 Jan 24.

引用本文的文献

1
A Novel Methylation-based Model for Prognostic Prediction in Lung Adenocarcinoma.一种用于肺腺癌预后预测的新型甲基化模型。
Curr Genomics. 2024 Feb 23;25(1):26-40. doi: 10.2174/0113892029277397231228062412.
2
CMaf-Inducing Protein Promotes LUAD Proliferation and Metastasis by Activating the MAPK/ERK Pathway.CMaf诱导蛋白通过激活MAPK/ERK信号通路促进肺腺癌增殖和转移。
Evid Based Complement Alternat Med. 2022 Sep 14;2022:2501846. doi: 10.1155/2022/2501846. eCollection 2022.
3
The predictive value of F-FDG PET/CT in an -mutated lung adenocarcinoma population.
F-FDG PET/CT在KRAS突变型肺腺癌人群中的预测价值。
Transl Cancer Res. 2022 Jul;11(7):2338-2347. doi: 10.21037/tcr-22-1726.
4
axis promotes lung adenocarcinoma progression and energy metabolism reprogramming.轴促进肺腺癌进展和能量代谢重编程。
Transl Lung Cancer Res. 2022 Jul;11(7):1405-1419. doi: 10.21037/tlcr-22-465.
5
Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer.非小细胞肺癌患者血浆外泌体的蛋白质组学分析
Transl Lung Cancer Res. 2022 Jul;11(7):1434-1452. doi: 10.21037/tlcr-22-467.
6
The extent of mediastinal lymph node dissection correlates with survival of small cell lung cancer patients after resection: a propensity score-matched cohort study analysis.纵隔淋巴结清扫范围与小细胞肺癌患者切除术后生存率相关：一项倾向评分匹配队列研究分析
Transl Lung Cancer Res. 2022 Jul;11(7):1453-1467. doi: 10.21037/tlcr-22-489.
7
Comparison of perioperative outcomes among non-small cell lung cancer patients with neoadjuvant immune checkpoint inhibitor plus chemotherapy, EGFR-TKI, and chemotherapy alone: a real-world evidence study.新辅助免疫检查点抑制剂联合化疗、EGFR-TKI与单纯化疗的非小细胞肺癌患者围手术期结局比较：一项真实世界证据研究
Transl Lung Cancer Res. 2022 Jul;11(7):1468-1478. doi: 10.21037/tlcr-22-476.
8
Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study.免疫检查点抑制剂在已有抗核抗体的非小细胞肺癌患者中的安全性和疗效：一项回顾性队列研究
Transl Lung Cancer Res. 2022 Jul;11(7):1420-1433. doi: 10.21037/tlcr-22-464.
9
Identification and validation of a ferroptosis-related prognostic risk-scoring model and key genes in small cell lung cancer.小细胞肺癌中铁死亡相关预后风险评分模型及关键基因的鉴定与验证
Transl Lung Cancer Res. 2022 Jul;11(7):1380-1393. doi: 10.21037/tlcr-22-408.
10
Identification of a three-gene expression signature and construction of a prognostic nomogram predicting overall survival in lung adenocarcinoma based on TCGA and GEO databases.基于TCGA和GEO数据库鉴定三基因表达特征并构建预测肺腺癌总生存期的预后列线图。
Transl Lung Cancer Res. 2022 Jul;11(7):1479-1496. doi: 10.21037/tlcr-22-444.